Aug 09, 2022 8:30am EDT SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15
Aug 04, 2022 8:30am EDT SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting
Aug 01, 2022 8:30am EDT SCYNEXIS Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME® (ibrexafungerp tablets) for Prevention of Recurrent Vaginal Yeast Infections
Jul 19, 2022 8:30am EDT SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the ISSVD XXVI World Congress and International Vulvovaginal Disease Update
Jul 14, 2022 8:30am EDT SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update
Jun 23, 2022 8:30am EDT SCYNEXIS Announces Initiation of New Phase 3b Study (VANQUISH) to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole
Jun 08, 2022 8:30am EDT SCYNEXIS Announces Submission of Supplemental New Drug Application of ibrexafungerp to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections
May 12, 2022 7:00am EDT SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update
